CY1107638T1 - Μονοκλωνο αντισωμα του παραγοντα viii που ακομη και οταν υπαρχει σε μοριακη περισσεια αδρανοποιει τον παραγοντα viii μονο εν μερει και μια μεθοδος παραγωγης ενος τετοιου αντισωματος - Google Patents

Μονοκλωνο αντισωμα του παραγοντα viii που ακομη και οταν υπαρχει σε μοριακη περισσεια αδρανοποιει τον παραγοντα viii μονο εν μερει και μια μεθοδος παραγωγης ενος τετοιου αντισωματος

Info

Publication number
CY1107638T1
CY1107638T1 CY20071100703T CY071100703T CY1107638T1 CY 1107638 T1 CY1107638 T1 CY 1107638T1 CY 20071100703 T CY20071100703 T CY 20071100703T CY 071100703 T CY071100703 T CY 071100703T CY 1107638 T1 CY1107638 T1 CY 1107638T1
Authority
CY
Cyprus
Prior art keywords
factor viii
ligands
factor
complex
way
Prior art date
Application number
CY20071100703T
Other languages
Greek (el)
English (en)
Inventor
Marc G Jacquemin
Jean-Marie R Saint-Remy
Original Assignee
D. Collen Research Foundation Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9916450.1A external-priority patent/GB9916450D0/en
Application filed by D. Collen Research Foundation Vzw filed Critical D. Collen Research Foundation Vzw
Publication of CY1107638T1 publication Critical patent/CY1107638T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY20071100703T 1999-07-14 2007-05-24 Μονοκλωνο αντισωμα του παραγοντα viii που ακομη και οταν υπαρχει σε μοριακη περισσεια αδρανοποιει τον παραγοντα viii μονο εν μερει και μια μεθοδος παραγωγης ενος τετοιου αντισωματος CY1107638T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14389199P 1999-07-14 1999-07-14
GBGB9916450.1A GB9916450D0 (en) 1999-07-14 1999-07-14 Ligands for use in therapeutic compounds for the treatment of hemostasis disorders
EP00949329A EP1194528B1 (en) 1999-07-14 2000-07-13 Monoclonal antibody for factor VIII, which even when present in molar excess inactivates factor VIII only in part and a method for producing such an antibody

Publications (1)

Publication Number Publication Date
CY1107638T1 true CY1107638T1 (el) 2013-04-18

Family

ID=26315767

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100703T CY1107638T1 (el) 1999-07-14 2007-05-24 Μονοκλωνο αντισωμα του παραγοντα viii που ακομη και οταν υπαρχει σε μοριακη περισσεια αδρανοποιει τον παραγοντα viii μονο εν μερει και μια μεθοδος παραγωγης ενος τετοιου αντισωματος

Country Status (11)

Country Link
EP (1) EP1194528B1 (cg-RX-API-DMAC7.html)
JP (2) JP4297207B2 (cg-RX-API-DMAC7.html)
AT (1) ATE356201T1 (cg-RX-API-DMAC7.html)
AU (1) AU781638B2 (cg-RX-API-DMAC7.html)
CA (1) CA2381125C (cg-RX-API-DMAC7.html)
CY (1) CY1107638T1 (cg-RX-API-DMAC7.html)
DE (1) DE60033814T2 (cg-RX-API-DMAC7.html)
DK (1) DK1194528T3 (cg-RX-API-DMAC7.html)
ES (1) ES2283308T3 (cg-RX-API-DMAC7.html)
PT (1) PT1194528E (cg-RX-API-DMAC7.html)
WO (1) WO2001004269A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
DK1222929T3 (da) 2001-01-11 2010-09-06 Life Sciences Res Partners Vzw Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom
AU2002313194B9 (en) * 2001-06-12 2008-06-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human-type anti-blood coagulation factor VIII antibody
EP1388544A1 (en) 2002-07-31 2004-02-11 D. Collen Research Foundation vzw Anti-idiotypic antibodies against factor VIII inhibitor and uses thereof
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
CA2535489C (en) 2003-08-14 2014-09-30 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
AU2005282380A1 (en) 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
ATE509957T1 (de) * 2005-07-29 2011-06-15 Life Sciences Res Partners Vzw An die a2-domäne bindende, humane inhibitorische anti-faktor-viii-antikörper
FR2892724B1 (fr) 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
FR2897868B1 (fr) * 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
NZ597452A (en) 2009-07-10 2013-10-25 Thrombogenics Nv Variants of plasminogen and plasmin
WO2011023805A1 (en) 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
EP2785739B1 (en) 2011-12-01 2017-03-15 ThromboGenics N.V. Improving trabeculectomy outcome
KR101395736B1 (ko) * 2012-07-10 2014-05-16 아주대학교산학협력단 인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
EP3426685A1 (en) 2016-03-10 2019-01-16 Oxurion NV Posterior ocular fibrosis inhibition by antagonizing placental growth factor
KR20200005635A (ko) * 2017-05-11 2020-01-15 브이아이비 브이지더블유 가변 면역글로불린 도메인의 글리코실화

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

Also Published As

Publication number Publication date
ATE356201T1 (de) 2007-03-15
DK1194528T3 (da) 2007-07-09
CA2381125C (en) 2013-04-23
EP1194528A1 (en) 2002-04-10
JP4297207B2 (ja) 2009-07-15
DE60033814T2 (de) 2007-11-08
AU6273000A (en) 2001-01-30
JP2003504045A (ja) 2003-02-04
JP4297225B2 (ja) 2009-07-15
CA2381125A1 (en) 2001-01-18
JP2008295455A (ja) 2008-12-11
AU781638B2 (en) 2005-06-02
EP1194528B1 (en) 2007-03-07
PT1194528E (pt) 2007-05-31
WO2001004269A1 (en) 2001-01-18
DE60033814D1 (de) 2007-04-19
ES2283308T3 (es) 2007-11-01

Similar Documents

Publication Publication Date Title
DK1194528T3 (da) Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistof
Eichler et al. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A
Boggio et al. Acquired hemophilia
Zacharski et al. Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding
ATE493148T1 (de) Antikörper zur hemmung der blutgerinnung und anwendungsverfahren dafür
Ortel Clinical and laboratory manifestations of anti-factor V antibodies
Panyutich et al. Identification of defensin binding to C1 complement
HUS1600041I1 (hu) VII-es véralvadási faktor-FC kiméra proteinek hemosztázis rendellenesség kezelésére
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
CY1118363T1 (el) Αντισωματα που ανοσοειδικως συνδεονται προς blys
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
PT833911E (pt) Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao
ATE551060T1 (de) Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
Ni et al. Activated thrombin‐activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin‐dependent plasmin generation on thrombin‐activated platelets
Lin et al. Leptospira immunoglobulin‐like protein B (LigB) binding to the C‐terminal fibrinogen αC domain inhibits fibrin clot formation, platelet adhesion and aggregation
Doolittle et al. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin
Mizumachi et al. Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis
EP1544214A4 (en) Non-neutralizing anti-aPC antibodies
Hansen et al. Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz–type protease inhibitor 2 domain of tissue factor pathway inhibitor
Bovenschen et al. Proteolytic cleavage of factor VIII heavy chain is required to expose the binding‐site for low‐density lipoprotein receptor‐related protein within the A2 domain
KR102469621B1 (ko) 혈장 단백질에 접합된 헤파린을 포함하는 치료용 apac 분자
RU2015143696A (ru) МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АНТИТРОМБИНА β
Naik et al. Application of “ATTEMPTS” for drug delivery
Takeyama et al. Protein S down‐regulates factor Xase activity independent of activated protein C: specific binding of factor VIII (a) to protein S inhibits interactions with factor IXa
Lollar Pathogenic antibodies to coagulation factors. Part II. Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, the protein C system and von Willebrand factor